Magnitude and determinants of CD4 recovery after haart resumption after 1 cycle of treatment interruption

Journal of Acquired Immune Deficiency Syndromes

Volumn 52, Issue 5, 2009, Pages 588-594

  Mussini, Cristina ^a   Touloumi, Giota ^b   Bakoyannis, Giorgos ^b   Sabin, Caroline ^c   Castagna, Antonella ^d   Sighinolfi, Laura ^e   Erikson, Lars E ^f   Bratt, Goran ^f   Borghi, Vanni ^a   Lazzarin, Adriano ^d   Cossarizza, Andrea ^g   Esposito, Roberto ^a  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^c ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^d VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^e Department of Infectious Diseases ^*  (Italy)

^f STOCKHOLM SÖDER HOSPITAL   (Sweden)

^g UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

HAART resumption; HIV infection; Immunological response; Prognostic factors; Treatment interruption; Virologic response

Indexed keywords

CD4 ANTIGEN; RNA DIRECTED DNA POLYMERASE INHIBITOR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CLINICAL TRIAL; CONTROLLED STUDY; CONVALESCENCE; DRUG EFFICACY; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; PROGNOSIS; TREATMENT RESPONSE; VIRUS LOAD; IMMUNOLOGY; MIDDLE AGED; RETROSPECTIVE STUDY; TREATMENT REFUSAL;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TREATMENT REFUSAL;

EID: 73349101555     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e3181b9e94d     Document Type: Article

References (30)

1. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med. 1998;338: 853-860.
2. Gehi AK, Ali S, Na B, et al. Self-reported medication adherence and cardiovascular events in patients with stable coronary heart disease: the heart and soul study. Arch Intern Med. 2007;167:1798-1803. (Pubitemid 47403069)
3. Bangsberg DR, Acosta EP, Gupta R, et al. Adherence-resistance relationships for protease and non-nucleoside reverse transcriptase inhibitors explained by virological fitness. AIDS. 2006;20:223-231.
4. Ananworanich J, Gayet-Ageron A, Le Braz M. Staccato Study Group; Swiss HIV Cohort Study. CD4-guided scheduled treatment interruptions compared with continuous therapy for patients infected with HIV-1: results of the Staccato randomised trial. Lancet. 2006;368:459-465.
5. Maggiolo F, Ripamonti D, Gregis G, et al. Effect of prolonged discontinuation of successful antiretroviral therapy on CD4 T cells: a controlled, prospective trial. AIDS. 2004;18:439-446.
6. + cell-count-guided treatment interruptions in chronic HIV-infected patients with good response to highly active antiretroviral therapy. AIDS. 2004;18:2381-2389.
7. Tarwater PM, Parish M, Gallant JE. Prolonged treatment interruption after immunologic response to highly active antiretroviral therapy. Clin Infect Dis. 2003;37:1541-1548.
8. 6 cells/l. AIDS. 2005;19:287-294.
9. + count-guided interruption of antiretroviral treatment. N Engl J Med. 2006;355:2283-2289.
10. Touloumi G, Pantazis N, Antoniou A, et al. Highly active antiretroviral therapy interruption: predictors and virological and immunologic consequences. J Acquir Immune Defic Syndr. 2006;42:554-561.
11. Touloumi G, Pantazis N, Stirnadel HA, et al. Rates and determinants of virologic and immunological response to HAART resumption after treatment interruption in HIV-1 clinical practice. J Acquir Immune Defic Syndr. 2008;49:492-498.
12. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94:496-509.
13. Panel of Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. Department of Health and Human Services. Updated 3 November 2008;1-139. Available at: http://www.aidsinfo.nih.gov/ ContentFiles/AdultandAdolescentGL. pdf. Accessed 22 February 2009.
14. Vittinghoff E, Malani HM, Jewell NP. Estimating patterns of CD4 lymphocyte decline using data from a prevalent cohort of HIV-1 infected individuals. Stat Med. 1994;13:1101-1108.
15. Lyles RH, Munoz A, Yamashita TE, et al. Natural history of human immunodeficiency virus type 1 viremia after seroconversion and proximal to AIDS in a large cohort of homosexual men. Multicenter AIDS Cohort Study. J Infect Dis. 2000;181:872-880.
16. Phillips AN, Gazzard BG, Clumeck N, et al. When should antiretroviral therapy for HIV be started? BMJ. 2007;334:76-78.
17. El-Sadr W. SMART Study Group. Re-initiation of ART in the CD4-guided ART Interruption Group in the SMART Study lowers risk of opportunistic disease or death [Abstract 36]. Paper presented at: 15th Conference on Retrovirus and Opportunistic Infections; 2008; Boston, MA.
18. + T cell homeostasis and function in advanced HIV disease. Science. 1997;277:112-116.
19. Meissner EG, Duus KM, Loomis R, et al. HIV-1 replication and pathogenesis in the human thymus. Curr HIV Res. 2003;1:275-285.
20. + T cell count after antiretroviral therapy in drug-naive HIV-positive patients. Immunogenet-ics. 2005;57:628-635.
21. Battegay M, Nuesch R, Hirschel B, et al. Immunological recovery and antiretroviral therapy in HIV-1 infection. Lancet Infect Dis. 2006;6: 280-287.
22. Bucy RP, Hockett RD, Derdeyn CA, et al. Initial increase in blood CD4 (+) lymphocytes after HIV antiretroviral therapy reflects redistribution from lymphoid tissues. J Clin Invest. 1999;103:1391-1398.
23. + T cell homeostasis and function in advanced HIV disease. Science. 1997;277:112-116.
24. Smith CJ, Sabin CA, Youle MS, et al. Factors influencing increases in CD4 cell counts in HIV-positive persons receiving long-term highly active antiretroviral therapy. J Infect Dis. 2004;190:1860-1868.
25. Staszewski S, Miller V, Sabin CA, et al. Determinants of sustainable CD4 lymphocyte count increases in response to antiretroviral therapy. AIDS. 1999;180:1050-1056.
26. Cozzi-Lepri A, Phillips AN, d'Arminio Monforte A, et al. When to start highly active antiretroviral therapy in chronically HIV-infected patients: evidence from the ICONA study. AIDS. 2001;15:983-990.
27. Landay A, da Silva BA, King MS, et al. Evidence of ongoing immune reconstitution in subjects with sustained viral suppression following 6 years of lopinavir-ritonavir treatment. Clin Infect Dis. 2007; 44; 749-754.
28. Pitrak DL, Bolanos J, Hershow R, et al. Discordant CD4 T lymphocyte responses to antiretroviral therapy for HIV infection are associated with ex vivo rates of apoptosis. AIDS. 2001;15:1317-1319.
29. Kaufman GR, Perrin L, Pantaleo G, et al. CD4 T-lymphocyte recovery in individuals with advanced HIV-1 infection receiving potent antiretroviral therapy for 4 years: the Swiss HIV Cohort Study. Arch Intern Med. 2003; 163:2187-2195.
30. Cossarizza A, Stent G, Mussini C, et al. Deregulation of the CD95/CD95L system in lymphocytes from patients with primary acute HIV infection. AIDS. 2000;14:345-355.